Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences®, which includes The American Journal of Managed Care®, Managed Healthcare Executive®, Pharmacy Times®, and Drug Topics®. She has been with MJH Life Sciences since 2011.
Laura has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions
September 28th 2020Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.
Pediatric Asthma Health Care Utilization Following Onset of COVID-19 Pandemic
September 25th 2020Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.
Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background
September 23rd 2020Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.
Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results
September 12th 2020The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.
Precision Medicine Could Yield Significant Cost Savings in RA Treatment
September 11th 2020A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.
Improved Treatment Options for SMA Present New Opportunities, Challenges
September 5th 2020There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.